# AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

> **NCT04673617** · PHASE1,PHASE2 · COMPLETED · sponsor: **Artiva Biotherapeutics, Inc.** · enrollment: 45 (actual)

## Conditions studied

- Non Hodgkin Lymphoma

## Interventions

- **DRUG:** AB-101
- **DRUG:** Rituximab
- **DRUG:** Interleukin-2
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Bendamustine

## Key facts

- **NCT ID:** NCT04673617
- **Lead sponsor:** Artiva Biotherapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-29
- **Primary completion:** 2025-10-06
- **Final completion:** 2025-10-06
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04673617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04673617, "AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04673617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*